Pfizer seen as cautious Buy with 10% annual return but faces patent cliff and dividend risks

Galmed's Aramchol boosts prostate cancer drug Xtandi's effectiveness in preclinical study, promising better treatment.

Galmed Pharmaceuticals announced preclinical results showing that combining Aramchol with Xtandi (enzalutamide) increased prostate cancer cell death by 3-4 times compared to Xtandi alone. Xtandi, a major prostate cancer drug with global sales of $8 b...